产品
编 号：F749384
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2151032-62-9
产品详情
生物活性：
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
体外研究：
Cendakimab (RPC4046; ABT 308; CC-93538) 完全中和肺上皮 A-549 细胞中 IL-13 诱导的胸腺和活化调节趋化因子，效力范围为 80 至 513 pM。
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
体外研究：
Cendakimab (RPC4046; ABT 308; CC-93538) 完全中和肺上皮 A-549 细胞中 IL-13 诱导的胸腺和活化调节趋化因子，效力范围为 80 至 513 pM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备